Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Completed Phase 1Phase 2 Interventional

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428
View directory record Official record
Conditions
Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions
UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 21, 2026, 6:52 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The MIRIA Acne Scar Study

NCT05597267
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
MIRIA Laser
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Miami, Florida • Waltham, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 4 Interventional Results available

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

NCT05919888
View directory record Official record
Conditions
Surgery, Surgical Site Infection, Cutibacterium Acnes, Prosthetic-joint Infection
Interventions
Povidone-Iodine, SURGX Wound Gel
Drug · Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Not applicable Interventional Results available

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

NCT00558831
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl Peroxide, Moisturizing Lotion
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Boise, Idaho • Carmel, Indiana • Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

NCT01015638
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and BPO 5% gel, Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars

NCT02103127
View directory record Official record
Conditions
Acne Scars
Interventions
755nm Alexandrite laser with lens array
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 21, 2026, 6:52 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT

NCT03333759
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Alma - Harmony XL Laser
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing OTC Acne Treatment to Prescription Regimen

NCT01237821
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BenzaClin, Effaclar
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 6:52 PM EDT
Terminated No phase listed Observational Results available

Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population

NCT00964119
View directory record Official record
Conditions
Acne
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 21, 2026, 6:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Not applicable Interventional

Do Wound Protectors Reduce Contamination in Total Shoulder Arthroplasty?

NCT06513182
View directory record Official record
Conditions
Cutibacterium Acnes
Interventions
No Alexis orthopaedic protector, Alexis orthopaedic protector
Other · Device
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

NCT04179175
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Rogers, Arkansas • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fractional Resurfacing Device for Treatment of Acne Scarring

NCT00585286
View directory record Official record
Conditions
Acne, Scar
Interventions
10,600 nm fractional carbon dioxide laser system
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 6:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

NCT05362929
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation
Interventions
Sciton Halo
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 6:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

NCT06673641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 21, 2026, 6:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

NCT04993066
View directory record Official record
Conditions
Pseudofolliculitis Barbae, Unwanted Hair, Pigmented Lesions, Vascular Lesion, Onychomycosis, Wrinkle, Acne
Interventions
GentleMax Pro Plus
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 21, 2026, 6:52 PM EDT